(+/-)-2,5-DIMETHOXY-4-BROMO-AMPHETAMINE HYDROBROMIDE suppliers

Symbol(GHS) 

GHS06

Signal word 

Danger

Hazard statements 

H302-H310-H330

Precautionary statements 

P264-P270-P301+P312-P330-P501-P262-P264-P270-P280-P302+P350-P310-P322-P361-P363-P405-P501-P260-P271-P284-P304+P340-P310-P320-P403+P233-P405-P501

Hazard Codes 

T+

Risk Statements 

26/27/28

Safety Statements 

28-36/37-45

RIDADR 

UN 2811 6.1/PG 2

WGK Germany 

3

RTECS 

SH0300000

HazardClass 

6.1(a)

PackingGroup 

I

Toxicity

A hallucinogenic (psychedelic) agent that is obtained by chemical synthesis. It may catalyze severe emotional problems or psychosis in predisposed individuals, and in large doses, produces peripheral arterial spasm which, if not treated, can lead to gangrene. DOB is a potent serotonin 5-HT2 agonist, and although the underlying mechanism of action for hallucinogens is not well understood, this may be related to its actions in the CNS. Symptoms include hyperreflexia, restlessness, perceptual alterations, and illusions, including changes in touch, taste, and odor, and the thinking process is substantially altered. At high doses, it causes hallucinations, loss of contact with reality, and pain and coldness in the extremities at toxic levels. Therapeutically, peripheral arterial spasm has been treated with intraarterial tolazoline hydrochloride. Its LD50 is in mice 80 mg/kg, i.v., in rats 8 mg/kg, i.p., in dogs 4 mg/kg. i.v., and in monkeys 2 mg/kg, i.v.